1. Home
  2. CFND vs PRPO Comparison

CFND vs PRPO Comparison

Compare CFND & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CFND

C1 Fund Inc.

N/A

Current Price

$5.36

Market Cap

36.5M

Sector

N/A

ML Signal

N/A

Logo Precipio Inc.

PRPO

Precipio Inc.

N/A

Current Price

$24.02

Market Cap

32.4M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
CFND
PRPO
Founded
N/A
N/A
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
36.5M
32.4M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
CFND
PRPO
Price
$5.36
$24.02
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
N/A
14.7K
Earning Date
N/A
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$22,800,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
30.95
52 Week Low
N/A
$3.90
52 Week High
N/A
$28.50

Technical Indicators

Market Signals
Indicator
CFND
PRPO
Relative Strength Index (RSI) N/A 55.72
Support Level N/A $22.50
Resistance Level N/A $26.00
Average True Range (ATR) 0.00 2.01
MACD 0.00 0.00
Stochastic Oscillator 0.00 52.44

Price Performance

Historical Comparison
CFND
PRPO

About CFND C1 Fund Inc.

C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Share on Social Networks: